Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336.SS · SHH
Company research
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS) is a China-based biopharmaceutical company founded in 2002 and listed on the Shanghai Stock Exchange, specializing in the research, development, production, and sale of innovative antibody drugs. The company is among the first in China dedicated exclusively to innovative antibody drug research, operating a mature integrated platform with cutting-edge technologies including monoclonal antibodies, bispecific antibodies, multispecific antibodies, and multifunctional recombinant proteins. Its key marketed products include YISAIPU (a tumor necrosis factor inhibitor for autoimmune rheumatic diseases), Xenopax/Jiannipa (a recombinant humanized anti-CD25 monoclonal antibody injection for kidney transplant rejection prevention), and Cipterbin/Saiputing (an anti-HER2 monoclonal antibody for breast cancer), with its portfolio targeting major disease areas such as autoimmune disorders, oncology, and immunology. Headquartered in Shanghai's Pilot Free Trade Zone and employing approximately 995 staff, the company houses the National Engineering Research Center for Antibody Drugs and continues to advance its pipeline with novel treatments, supported by multiple national-level science and technology initiatives.
Research reports
In-depth company report positioning 三生国健 as a leading antibody drug developer focused on autoimmune diseases, highlighting a broad pipeline (608, 611, 613, 610 and early-stage assets) and the global out-licensing of PD-1/VEGF 双抗 707 to Pfizer as key growth drivers. The authors forecast 2026–2028 EPS and assign an “增持” rating, while flagging policy changes, innovation risk, rising competition and commercialization pressures (pricing,医保降价,集采) as major risks.
中邮证券 · May 8, 2026三生国健(688336) 授权收入增厚利润，自免管线稳步推进迈入收获期Detailed broker report analyzing 2025 results, concluding that large one-off licensing income from the 707 project and other authorizations significantly boosted revenue and profit while core autoimmune products and CDMO contributed steadily. It maintains a “买入” rating with explicit 2026–2028 revenue and net profit forecasts, and emphasizes long-term upside from the IL‑17A, IL‑4R, IL‑1β and IL‑5 pipelines, but warns about licensing income uncertainty, 集采和医保政策对收入的影响, R&D failure and intensified competition as key risks.
富途牛牛（券商研究转载平台） · October 26, 2025三生国健(688336)：业绩同环比增速稳健在研项目稳步推进Earnings-focused note describing robust year-on-year and quarter-on-quarter growth in 2025 Q3 revenue and net profit, driven mainly by authorization income from the 707 collaboration with Pfizer and expansion of CDMO business. The report raises 2025–2027 EPS and maintains a “买入” stance, highlighting the receipt of Pfizer’s upfront payment, strong cash-flow improvement, and steady progress of late-stage autoimmune programs (608, 611, 613 and 626/627) while cautioning on regulatory, FX and key-person risks.